2022
DOI: 10.1002/ijc.34282
|View full text |Cite
|
Sign up to set email alerts
|

Emerging role of oncogenic long noncoding RNA as cancer biomarkers

Abstract: The view of long noncoding RNAs as nonfunctional "garbage" has been definitely outdated by the large body of evidence indicating this class of ncRNAs as "golden junk", especially in precision oncology. Indeed, in light of their oncogenic role and the higher expression in multiple cancer types compared with paired adjacent tissues, the clinical interest for lncRNAs as diagnostic and/or prognostic biomarkers has been rapidly increasing. The emergence of large-scale sequencing technologies, their subsequent diffu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
25
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 38 publications
(25 citation statements)
references
References 184 publications
0
25
0
Order By: Relevance
“…LncRNAs are RNA molecules longer than 200 nucleotides that do not carry protein coding capacity [ 49 ]. Several lncRNAs have been shown to be crucial players in different cancers [ 50 , 51 , 52 , 53 ] and many of them are considered as new biomarkers [ 54 ].…”
Section: Resultsmentioning
confidence: 99%
“…LncRNAs are RNA molecules longer than 200 nucleotides that do not carry protein coding capacity [ 49 ]. Several lncRNAs have been shown to be crucial players in different cancers [ 50 , 51 , 52 , 53 ] and many of them are considered as new biomarkers [ 54 ].…”
Section: Resultsmentioning
confidence: 99%
“…Long non-coding RNAs (lncRNAs) are RNA sequences of about 200 nucleotides that play important roles in the regulation of multiple biological activities, including cell proliferation, differentiation, autophagy, and apoptosis. Accumulating evidence shows that the impairment of lncRNA regulation can lead to the development of chemoresistance and metastasis in many types of cancers, including ovarian cancer [ 3 , 36 , 37 , 38 , 39 ]. Different from lncRNAs, microRNAs (miRNAs) are smaller (16–30 nucleotides) noncoding RNAs that can regulate gene expression by targeting specific 3′-untranslated regions (3′-UTR) of target mRNA.…”
Section: Metformin As Regulator Of Cancer Cell Progression and Resist...mentioning
confidence: 99%
“…Different from lncRNAs, microRNAs (miRNAs) are smaller (16–30 nucleotides) noncoding RNAs that can regulate gene expression by targeting specific 3′-untranslated regions (3′-UTR) of target mRNA. Both lncRNAs and miRNAs regulate important cell processes and have been used as markers in many cancerous and non-cancerous diseases [ 36 , 37 , 39 , 40 , 41 , 42 , 43 ]. Importantly, these two types of noncoding RNAs are not independent of each other, but there is a cross-talk in the regulation of their expression that allows lncRNAs to regulate miRNA expression and vice versa [ 40 ].…”
Section: Metformin As Regulator Of Cancer Cell Progression and Resist...mentioning
confidence: 99%
“…Other tissue-specific lncRNAs differentially expressed in some cancers represent potential biomarkers for cancer diagnosis or prognosis. MALAT1 and HOTAIR have been approved as diagnostic markers in gastric carcinoma and PCA3 as a biomarker for the early diagnosis and prognosis of prostate cancer [ 35 , 36 ].…”
Section: Ncrnas In Posttranscriptional Regulationmentioning
confidence: 99%
“…Currently, licensed patents or clinical trials focused on the potential use of lncRNAs as diagnostic/prognostic biomarkers do not include lncRNAs involved in the regulation of the expression of PAS components [ 36 ].…”
Section: Pa-targeting Ncrnas As Cancer Biomarkersmentioning
confidence: 99%